Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED
  5. VGI Health Technology Limited
  6. Summary
    VTL   AU0000152597

VGI HEALTH TECHNOLOGY LIMITED

(VTL)
End-of-day quote NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED  -  2022-06-28
0.0300 AUD   -70.00%
10/04VGI Health Technology Limited NAFLD/NASH Phase II Clinical Study
AW
10/04Vgi Health Technology Limited (nsx : VTL) NAFLD/NASH Phase II Clinical Study
AQ
09/25VGI Health Technology Limited Receives Ethics Approval for US Clinical Study
AW
 SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
02/15/2022 02/23/2022 03/11/2022 03/28/2022 06/29/2022 Date
0.19 0.1 0.1 0.1 0.03 Last
10 7119 30000 32 22574 Volume
+5.56% -47.37% 0.00% 0.00% -70.00% Change
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 -3,90 M -2,50 M -2,50 M
Net cash position 2021 0,02 M 0,01 M 0,01 M
P/E ratio 2021 -7,08x
Yield 2021 -
Sales 2022 0,01  0,01  0,01 
Net income 2022 -7,87 M -5,04 M -5,04 M
Net Debt 2022 1,76 M 1,13 M 1,13 M
P/E ratio 2022 -0,53x
Yield 2022 -
Capitalization 4,15 M 2,65 M 2,65 M
EV / Sales 2021 -
EV / Sales 2022 435 205 817x
Nbr of Employees -
Free-Float 0,87%
More Financials
Company
VGI Health Technology Limited is focused on researching, developing, distribution and marketing a range of health and therapeutic products and technologies. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines, including nE1-Heart and nE1-Elite. nE1-Heart product is targeting maintenance of heart health tocotrienols have a... 
More about the company
All news about VGI HEALTH TECHNOLOGY LIMITED
10/04VGI Health Technology Limited NAFLD/NASH Phase II Clinical Study
AW
10/04Vgi Health Technology Limited (nsx : VTL) NAFLD/NASH Phase II Clinical Study
AQ
09/25VGI Health Technology Limited Receives Ethics Approval for US Clinical Study
AW
09/13VGI Health Technology Limited NAFLD/NASH PhaseII Clinical Study Recruits 1st Patient
AW
09/13Vgi Health Technology Limited (nsx : VTL) NAFLD/NASH PhaseII Clinical Study Recruits 1st P..
AQ
08/10VGI Health Technology Limited Auditor Raises 'Going Concern' Doubt
CI
08/09Vgi Health Technology : Annual Report for the year ended 30 June 2022
PU
08/09VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30,..
CI
07/28Vgi Health Technology : June 2022 Quarterly Report
PU
07/28Vgi Health Technology : June 2022 Quarterly Update
PU
07/28VGI Health Technology Limited June 2022 Quarterly Update
AW
07/28Vgi Health Technology Limited (nsx : VTL) June 2022 Quarterly Update
AQ
07/04VGI Health Technology Limited Clinical Study Begins Recruitment of Patients
AW
07/04Vgi Health Technology : NAFLD/NASH Phase II Clinical Study begins recruitment of patients
PU
06/02Vgi Health Technology : Results of Special General Meeting held 3 June 2022
PU
More news
News in other languages on VGI HEALTH TECHNOLOGY LIMITED
08/10L'auditeur de VGI Health Technology Limited soulève un doute sur la pérennité de l'entr..
08/09VGI Health Technology Limited annonce ses résultats pour l'exercice complet terminé le ..
2021Vgi Health Technology Limited annonce ses résultats pour l'exercice complet terminé le ..
More news
Chart VGI HEALTH TECHNOLOGY LIMITED
Duration : Period :
VGI Health Technology Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Glenn Tong CEO, Managing Director & Executive Director
Ian Forbes Chief Financial Officer
Louis James Panaccio Independent Non-Executive Chairman
David Kingston Chief Scientific Officer
Jiayi Yu Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
VGI HEALTH TECHNOLOGY LIMITED-88.00%3
REGENERON PHARMACEUTICALS, INC.15.89%78 242
VERTEX PHARMACEUTICALS35.99%76 586
BIONTECH SE-46.65%33 422
WUXI APPTEC CO., LTD.-39.54%29 123
GENMAB A/S5.32%23 876